Biofrontera (NASDAQ:BFRI) Stock Rating Upgraded by Wall Street Zen

Biofrontera (NASDAQ:BFRI) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Several other research firms have also commented on BFRI. Zacks Research lowered shares of Biofrontera from a “hold” rating to a “strong sell” rating in a research note on Friday, July 3rd. Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Biofrontera currently has a consensus rating of “Reduce”.

Biofrontera Stock Performance

Shares of Biofrontera stock opened at $1.09 on Friday. Biofrontera has a 12 month low of $0.55 and a 12 month high of $1.21. The firm has a market capitalization of $13.95 million, a P/E ratio of -1.12 and a beta of 0.81. The company has a current ratio of 1.20, a quick ratio of 1.09 and a debt-to-equity ratio of 0.78. The business has a fifty day simple moving average of $0.97 and a two-hundred day simple moving average of $0.93.

Biofrontera (NASDAQ:BFRI) last released its earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29). The business had revenue of $10.08 million during the quarter, compared to analysts’ expectations of $10.25 million. Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%. On average, equities analysts forecast that Biofrontera will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC lifted its stake in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.08% of the stock is currently owned by institutional investors.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.